Moderna

YTD

ALL

Trade Moderna 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

4,700

Employees4,700

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

4,700

Employees4,700

MRNA Key Statistics

Market cap

24.53B

Market cap24.53B

Price-Earnings ratio

-7.59

Price-Earnings ratio-7.59

Dividend yield

—

Dividend yield—

Average volume

7.41M

Average volume7.41M

High today

$63.28

High today$63.28

Low today

$61.06

Low today$61.06

Open price

$61.63

Open price$61.63

Volume

4.55M

Volume4.55M

52 Week high

$85.60

52 Week high$85.60

52 Week low

$22.28

52 Week low$22.28

Stock Snapshot

As of today, Moderna(MRNA) shares are valued at $61.66. The company's market cap stands at 24.53B, with a P/E ratio of -7.59.

As of 2026-07-20, Moderna(MRNA) stock has fluctuated between $61.06 and $63.28. The current price stands at $61.66, placing the stock +1.0% above today's low and -2.6% off the high.

The Moderna(MRNA)'s current trading volume is 4.55M, compared to an average daily volume of 7.41M.

During the past year, Moderna(MRNA) stock moved between $22.28 at its lowest and $85.60 at its peak.

MRNA News

Simply Wall St 2d

Does Moderna’s New mRNA-4200 Trial Quietly Rebalance Its Long-Term Oncology Risk Profile?

Earlier this month, Moderna announced it had dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an mRNA-based, tumor-targeted cancer antigen ther...

Investing.com 3d

Moderna president Stephen Hoge sells $3.6m in stock - Investing.com

...

TipRanks 4d

Arbutus Biopharma receives $178M settlement agreement from Moderna

Arbutus (ABUS) also announced the receipt of approximately $178M from Moderna (MRNA), representing the company’s share of the noncontingent payment under the se...

Analyst ratings

69%

of 26 ratings

Buy

15.4%

Hold

69.2%

Sell

15.4%

More MRNA News

Simply Wall St 5d

Moderna Stock Looks Stretched On Sales But Reasonable On Momentum

Moderna stock has surged 118.5% year to date, yet the company screens as expensive on Simply Wall St's broader valuation checks. This raises a clear question ab...

People also own

Based on the portfolios of people who own MRNA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.